Pharma News, 2015

Eli Lilly ($LLY) is shutting down a massive, costly clinical trial after its lead drug came up short in cardiovascular disease, dealing a major blow to the company's pipeline.

The patent cliff crushed these Big Pharma companies, and now their only opportunity for sustainable growth might be to go shopping for a rival.

Merck promoted Stefan Oschmann to be its new chief executive as the German drugmaker looks to revitalise its business by betting on a new generation of cancer treatments.

Ready for the lung cancer showdown between Merck & Co.

GlaxoSmithKline ($GSK) has one less tool for propping up its top line.

October 09, 2015.

DUBLIN, Oct.

When the next influenza pandemic hits our shores, UK hospitals must be prepared to conduct trials into the effectiveness of available antiviral drugs, according to the conclusions of a leading panel o...

October 8, 2015,  Bloomberg Businessweek Reprints.

Sanofi and its subsidiary Genzyme today announced positive new five-year investigational data from the extension study of Lemtrada® (alemtuzumab) for patients with relapsing remitting multipl...

SANTA CLARA, Calif.

Sanofi decided several years ago that it would shutter a plant in the Kansas City, MO, area after attempts to sell it turned up no deal.